0001157523-23-000779.txt : 20230509 0001157523-23-000779.hdr.sgml : 20230509 20230509080028 ACCESSION NUMBER: 0001157523-23-000779 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 23900044 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 8-K 1 a53395899.htm AGENUS INC. 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
                                                                                                                                                                                                                             

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2023


AGENUS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
000-29089
06-1562417
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)


3 Forbes Road
Lexington, MA

02421
(Address of principal executive offices)
(Zip Code)

781-674-4400
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.01 par value per share
 
AGEN
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company   ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
Item 2.02             Results of Operations and Financial Condition.
 
On May 9, 2023, Agenus Inc. announced its financial results for the quarter ended March 31, 2023.  In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
 
Item 9.01             Financial Statements and Exhibits.
 
 
(d) Exhibit
 
The following exhibit is furnished herewith:

              99.1     Press Release dated May 9, 2023

 SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
AGENUS INC.
 
 
 
Date: May 9, 2023
By:
/s/ Christine M. Klaskin
 
 
 
 
 
Christine M. Klaskin
 
 
VP, Finance

EX-99.1 2 a53395899ex99_1.htm EXHIBIT 99.1
Exhibit 99.1

Agenus Provides Corporate Update and First Quarter 2023 Financial Results

  • At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments
  • Botensilimab/balstilimab combination data update selected for late-breaking oral session at the ESMO-GI conference in June 2023
  • FDA granted Fast Track Designation to the botensilimab/balstilimab combination in colorectal cancer in April 2023
  • At a plenary session at SGO, botensilimab/balstilimab combination showed 33% overall response rate in platinum-resistant ovarian cancer patients
  • Phase II ACTIVATE trials expected to fully enroll in second half of 2023
  • AGEN2373 monotherapy data to be presented at ASCO in June 2023
  • Balstilimab/zalifrelimab data in the treatment of sarcoma to be presented at ASCO oral session in June 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--May 9, 2023--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023.

"With over 350 patients dosed with botensilimab in our Phase 1 study, we have demonstrated 20-50% response rates in 9 solid tumor cancers. These results suggest that botensilimab could provide significant benefit to patients who have not responded to or failed other available treatments,” said Dr. Garo Armen, Chief Executive Officer of Agenus. “Agenus is committed to advancing our development programs to make botensilimab available to patients ASAP."

Botensilimab Combination

Unprecedented activity in 70 patients with non-MSI-H colorectal cancer and 24 patients with recurrent platinum resistant/refractory ovarian cancer:

  • Agenus presented botensilimab/balstilimab combination data at a late-breaking oral session at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) in January 2023 and at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer in March 2023
  • The combination showed unprecedented responses and survival benefit in 70 patients with non-microsatellite instability-high (non-MSI-H) colorectal cancer, including:
    • 12-month overall survival of 63% (compared to 25% reported for standard of care) 1,2
    • Overall response rate of 23% (compared to 1-2%1,2 reported for standard of care and 1-5%3,4 reported for other PD-(L)1 + CTLA-4 combinations)
  • In April 2023, the FDA granted Fast Track Designation to the botensilimab/balstilimab combination for the treatment of non-MSI-H/deficient mismatch repair (dMMR) metastatic colorectal cancer patients without active liver involvement who are resistant or intolerant to fluoropyrimidine, oxaliplatin, or irinotecan, and have also received a VEGF inhibitor, an EGFR inhibitor, and/or a BRAF inhibitor
  • Agenus is conducting a global, randomized Phase 2 trial in this patient population under its ACTIVATE trial program, and a global Phase 3 trial is expected to commence in 2023
  • In 24 ovarian cancer patients who were resistant or refractory to platinum chemotherapy, the botensilimab/balstilimab combination showed a 33% response rate (compared to ~10% reported for standard of care5 and 3-10% for other PD-(L)1 + CTLA-4 combinations6,7)
  • Agenus continues to enroll PD-(L)1 relapsed/refractory NSCLC patients in its Phase 1b study and plans to launch a randomized phase 3 study if the previously reported ~50% response rates continue

Upcoming Presentations

  • Updated data on the botensilimab/balstilimab combination in non-MSI-H metastatic colorectal cancer patients selected for a late breaking oral presentation at the upcoming ESMO World Congress on Gastrointestinal Cancer (ESMO-GI), to be held June 18 – July 1, 2023 in Barcelona, Spain
  • Data from a single-arm, open-label Phase 2 study of balstilimab and zalifrelimab (1st generation CTLA-4) plus doxorubicin in patients with advanced sarcomas selected for oral presentation at the ASCO 2023 Annual Meeting, to be held June 2-6 in Chicago, IL
  • Complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 in patients with advanced solid tumors will also be presented in a poster discussion at ASCO

Clinical Pipeline and Corporate Partnerships

Additional presentation at ASCO involving Agenus's clinical pipeline involving collaborations include:

  • Abstract #424868: Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA)
  • Abstract # TPS6104: Phase 2 Trial of Retifanlimab (anti–PD-1) in Combination With INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as First-Line Treatment in Patients With PD-L1–Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
  • Abstract #2599: A Phase 1/2 Study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) With Advanced Solid Tumors
  • Abstract #2541: A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers

Agenus shareholders received dividend of shares in MiNK Therapeutics (NASDAQ: INKT)

On May 1st, 2023, Agenus distributed a dividend of approximately 5,000,000 shares it owned of its subsidiary MiNK Therapeutics’ common stock to shareholders who held Agenus shares as of April 17, 2023, with a ratio of 0.0146 shares of MiNK (NASDAQ: INKT) per share of Agenus. The announced dividend distribution preceded MiNK's presentation of its lead product, agenT-797, an allo-INKT cell therapy, showing clinical and biomarker responses in solid tumor cancers at AACR in April 2023. This distribution allows Agenus shareholders to benefit from future growth of MiNK through direct ownership. The shares that were distributed as part of this dividend were not part of a new stock offering.

First Quarter 2023 Financial Results:

We ended our first quarter 2023 with a cash, cash equivalent and short-term investment balance of $189.2 million, compared to $193.4 million at December 31, 2022. Since quarter end we have raised $13.6 million through sales under our at market issuance sales agreement.

For the first quarter ended March 31, 2023, we recognized revenue of $22.9 million and incurred a net loss of $70.9 million (including non-cash expenses of $24.9 million) or $0.22 per share.

Financial Highlights
(in thousands, except per share data)
(unaudited)




 


March 31,

 

December 31,



2023

 

2022





 
Cash, cash equivalents and short-term investments

$

189,233

 


$

193,358

 





 




 


Three months ended March 31,



2023

 

2022





 
Revenues, research and development

$

2,612

 


$

6,740

 

Revenues, non-cash royalty

 

19,106

 


 

17,634

 

Revenues, other

 

1,184

 


 

1,567

 





 
Total Revenue

 

22,902

 


 

25,941

 





 




 
Research and development expenses

 

57,118

 


 

42,442

 

General and administrative expenses

 

18,237

 


 

18,953

 

Cost of service revenue

 

2,294

 


 

543

 

Other (income) loss

 

(721

)


 

191

 

Non-cash interest expense

 

17,273

 


 

14,952

 

Non-cash contingent consideration fair value adjustment

 

(406

)


 

(536

)

Net loss

$

(70,893

)


$

(50,604

)





 
Net loss per share attributable to Agenus Inc. common stockholders

$

(0.22

)


$

(0.19

)





 
Cash used in operations

$

58,526

 


$

52,391

 

Non-cash operating expenses

$

24,935

 


$

21,069

 

Conference Call

Date: May 9, 2023, 8:30am ET
Dial-in numbers: 646-307-1963 (US-NY) & 800-715-9871 (Ex-US)
Event ID: 9144113

Webcast

A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/v54y2wy9.

References

1 Mayer et al. NEJM 2015
2 Grothey et al. Lancet 2013
3 Chen et al. JAMA Oncol. 2020
4 Overman et al. ASCO 2016
5 Mutch DG, et al. J Clin Oncol. 2007;25(19): 2811-2818
6 https://clinicaltrials.gov/ct2/show/results/NCT01928394
7 Hinchcliff et al. Gynecologic Oncology 2021

About Botensilimab

Botensilimab is a novel, multifunctional CTLA-4 investigational antibody that has been designed to extend clinical benefits to “cold” tumors that have not historically responded to standard of care or investigational therapies, as well as to expand clinical benefit in “hot” tumors, where immunotherapies are approved but benefit only a minority of patients. In addition to binding to the CTLA-4 receptor, its Fc-enhanced structure induces a memory immune response, downregulates regulatory T cells, activates existing T cells, as well as primes and expands new T cells, thereby promoting a more effective and durable immune response to cancer.

In a Phase 1 clinical study of more than 350 patients, botensilimab has demonstrated clinical responses in nine different cold and treatment-refractory solid tumor cancers, either alone or in combination with Agenus’ PD-1 antibody, balstilimab (data presented at ASCO GI 2023, SGO 2023, SITC 2022, and CTOS 2022). Agenus is conducting global, randomized Phase 2 trials in non-MSI-H colorectal cancer, melanoma, and pancreatic cancer as part of its ACTIVATE trial programs. Additional information about these botensilimab trials can be found at www.clinicaltrials.gov under the identifiers NCT05608044, NCT05630183, and NCT05529316, respectively. A global Phase 3 trial in non-MSI-H colorectal cancer is expected to launch in 2023.

About AGEN2373

AGEN2373 is a novel anti-CD137 agonist that has been designed to activate T and NK cells while mitigating liver toxicities common to the CD137 target class. CD137 (4-1BB) is an activating receptor expressed on T and NK cells. Upon binging to CD137, AGEN2373 is designed to stimulate the growth and activation of cytotoxic T and NK cells, triggering a lasting memory response to cancer. AGEN2373 binds to a unique epitope designed to achieve this response specifically within the tumor microenvironment. This selective binding is designed to avoid serious side effects associated with CD137 activation in the liver that have been reported by competitor molecules. AGEN2373 has demonstrated preliminary clinical activity and has been well tolerated by patients without signs of liver toxicity (Tolcher et al. ASCO 2021).

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ and Twitter handle @MiNK_iNKT.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contacts

Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

EX-101.SCH 3 agen-20230509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 agen-20230509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 agen-20230509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2023
Entity File Number 000-29089
Entity Registrant Name AGENUS INC.
Entity Central Index Key 0001098972
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 06-1562417
Entity Address, Address Line One 3 Forbes Road
Entity Address, City or Town Lexington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code 781
Local Phone Number 674-4400
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol AGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 a53395899_htm.xml IDEA: XBRL DOCUMENT 0001098972 2023-05-09 2023-05-09 false 0001098972 DE NASDAQ 8-K 2023-05-09 AGENUS INC. 000-29089 06-1562417 3 Forbes Road Lexington MA 02421 781 674-4400 false false false false Common Stock, $0.01 par value per share AGEN false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://agenusbio.com./role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode, dei:SecurityExchangeName - a53395899.htm 11 a53395899.htm a53395899ex99_1.htm agen-20230509.xsd agen-20230509_lab.xml agen-20230509_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a53395899.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "a53395899.htm" ] }, "labelLink": { "local": [ "agen-20230509_lab.xml" ] }, "presentationLink": { "local": [ "agen-20230509_pre.xml" ] }, "schema": { "local": [ "agen-20230509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "agen", "nsuri": "http://agenusbio.com./20230509", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "a53395899.htm", "contextRef": "c20230509to20230509", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://agenusbio.com./role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "a53395899.htm", "contextRef": "c20230509to20230509", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://agenusbio.com./role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001157523-23-000779-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-23-000779-xbrl.zip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end